Skip to main content Skip to navigation
CD23 APC
Product Details
Down Arrow Up Arrow


BD™
CD23A; Fc-epsilon-RII; FCER2; FCE2; IGEBF; BLAST-2; CLEC4J; Leu-20
Human
Mouse BALB.B IgG1, κ
Epstein-Barr Virus Transformed Cell Line
Flow cytometry
25 μg/mL
5 μL
2208
Phosphate buffered saline with gelatin and 0.1% sodium azide.
CE_IVD


Preparation And Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

335036 Rev. 1
Antibody Details
Down Arrow Up Arrow
EBVCS-5

CD23 is intended for in vitro diagnostic use in the identification of cells expressing CD23 antigen, using a BD FACS™ brand flow cytometer.

The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.

335036 Rev. 1
Format Details
Down Arrow Up Arrow
APC
Allophycocyanin (APC), is part of the BD family of phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 651 nm and an emission maximum (Em Max) at 660 nm. APC is designed to be excited by the Red (627-640 nm) laser and detected using an optical filter centered near 660 nm (e.g., a 660/20 nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
APC
Red 627-640 nm
651 nm
660 nm
335036 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "335036" on CiteAb

Development References (19)

  1. Capron M, Jouault T, Prin L, et al. Functional study of a monoclonal antibody to IgE Fc receptor (Fc epsilon R2) of eosinophils, platelets, and macrophages.. J Exp Med. 1986; 164(1):72-89. (Biology). View Reference
  2. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  3. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. H42-A2. 2007. (Biology).
  4. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
  5. Erlanson M, Gronlunk E, Lofvenberg E, Roos G, Lindh J. Expression of activation markers CD23 and CD69 in B–cell non-Hodgkin's lymphoma. Eur J Haematol. 1998; 60:125-132. (Biology).
  6. Gordon J, Rowe M, Walker L, Guy G. Ligation of the CD23,p45 (Blast-2, EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. Eur J Immunol. 1986; 16:1075-1080. (Biology).
  7. Gordon J, Webb A, Walker L, Guy G, Rowe M. Evidence of an association between CD23 and the receptor for a low molecular weight B-cell growth factor. Eur J Immunol. 1986; 16:1627. (Biology).
  8. Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
  9. Kikutani H, Inui S, Sato R, et al. Molecular structure of human lymphocyte receptor for immunoglobulin E.. Cell. 1986; 47(5):657-65. (Biology). View Reference
  10. Kikutani H, Suemura M, Owaki H, et al. Fc epsilon receptor, a specific differentiation marker transiently expressed on mature B cells before isotype switching.. J Exp Med. 1986; 164(5):1455-69. (Biology). View Reference
  11. Kintner C, Sugden B. Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr Virus. Nature. 1981; 294:458-460. (Biology).
  12. NCCLS document. 2001. (Biology).
  13. Nadler LM. Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II: Human B Lymphocytes. New York, NY: Springer-Verlag; 1986:25-26.
  14. Pallesen G. McMichael AJ, ed. Leucocyte Typing III: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1987.
  15. Sarfati M, Ishihara H, Delespesse G. CD23 Workshop Panel report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:530-533.
  16. Sarfati M. Kishimoto T, Kikutani H, von dem Borne AEGK, et al, eds, ed. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing, Inc; 1998:144-147.
  17. Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
  18. Thorley-Lawson D, Nadler L, Bhan A, Schooley R. Blast-2 (EBVCS), an early cell surface marker of human B cell activation, is superinduced by Epstein Barr Virus. J Immunol. 1985; 134:3007-3012. (Biology).
  19. Yukawa K, Kikutani H, Owaki H, et al. A B-cell– specific differentiation antigen, CD23, is a receptor for IgE (FcεR) on lymphocytes. J Immunol. 1987; 138:2576-2580. (Biology).
View All (19) View Less
335036 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For In Vitro Diagnostic Use.

 

23-22942-00

Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.